| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALZN | Common Stock | Purchase | $688 | +1,000 | +0.13% | $0.6882 | 771,699 | 19 Apr 2024 | By Ault Lending, LLC | F1, F2 |
| holding | ALZN | Common Stock | 166,865 | 19 Apr 2024 | Direct | ||||||
| holding | ALZN | Common Stock | 996,197 | 19 Apr 2024 | By Ault Life Sciences, Inc. | F3 | |||||
| holding | ALZN | Common Stock | 5,498 | 19 Apr 2024 | By Ault Life Sciences Fund, LLC | F4 |
| Id | Content |
|---|---|
| F1 | The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $0.6882. The range of purchase prices on the transaction date was $0.6819 to $0.6895 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. |
| F2 | Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Ault Alliance, Inc. ("AAI"). Mr. Ault, the Executive Chairman of AAI, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending. |
| F3 | Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc. |
| F4 | Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC. |